7 results about "Obsessive-compulsive disorders" patented technology

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

The application belongs to the technical field of medicines, and relates to an N-H aporphine nitrogen-containing heterocyclic derivative, a preparation method and application thereof.The N-H aporphine nitrogen-containing heterocyclic derivative comprises a compound shown in a general formula M, isomers thereof and pharmaceutically acceptable salts or hydrates thereof.The application introduces a nitrogen-containing heterocyclic ring into an aporphine derivative, and the disclosed N-H aporphine nitrogen-containing heterocyclic derivative can be applied in the preparation of medicines for preventing and / or treating obesity, urinary incontinence, depression, anxiety, obsessive-compulsive disorder, epilepsy, schizophrenia, pain, diabetes and drug addiction.

The application relates to application of Lactobacillus murinus in preparation of a drug for treating obsessive-compulsive disorder. The application provides application of Lactobacillus murinus in preparation of a drug for treating obsessive-compulsive disorder, two different OCD mouse models are used to systematically evaluate the intervention effect of Lactobacillus murinus on obsessive-compulsive behavior, and the potential molecular mechanism is preliminarily explored. The results show that the intervention of Lactobacillus murinus can effectively improve the anxiety and obsessive-compulsive behavior of OCD model mice. Further mechanism research finds that the intervention effect may be related to the increase of the activity of excitatory neurons in the medial prefrontal cortex (mPFC) of Lactobacillus murinus.

The present application relates to a method for treating obsessive-compulsive disorder, comprising: a) identifying one or more specific brain regions exhibiting abnormal activation in a subject; and b) targeting the one or more specific brain regions, inhibiting or disrupting neuronal activity in the brain region(s), or interrupting or blocking neuronal signals in the brain region(s) of the subject.

A pharmaceutical composition for treating obsessive-compulsive disorder is provided. The present invention relates to (1) a pharmaceutical composition comprising a dopamine D1 receptor agonist as an effective ingredient for treating obsessive-compulsive disorder, and / or (2) a pharmaceutical composition comprising a dopamine D1 and D2 receptor stimulator, which is administered in combination with a dopamine D2 receptor inhibitor for the purpose of stimulating the dopamine D1 receptor in the striatum, and / or (3) a pharmaceutical composition comprising a dopamine D2 receptor inhibitor, which is administered in combination with a dopamine D1 and D2 receptor stimulator.

Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.